Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Bullboard Posts
Post by caochuanshengon Jun 23, 2016 1:33pm
102 Views
Post# 24991861

question :THE COMPANY HAS 4 PAPE LINE

question :THE COMPANY HAS 4 PAPE LINEthe comany has 4 papeline, is it mean Phase 3 Confirmatory Study for AA amyloidosis fail the papeline sarcoidosis fail other?

another questions are that is it possible Phase 3 can become success?

what is this news mean:

LAVAL, QC, June 2, 2016 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a drug development company focused on rare diseases, and Pharmascience Inc. ("Pharmascience"), a leading manufacturer of generic drugs, today announced the exercise of Pharmascience's right to convert its 10.4% interest (the "Units") in BHI Limited Partnership ("BHI LP") into 6,350,638 common shares of the Company. Following the transaction, BHI LP will be wholly-owned by BELLUS Health.

"This conversion is the final step to the completion of our capital structure's simplification that started in 2012", said Roberto Bellini, President and Chief Executive Officer of BELLUS Health. "The next milestone in our business plan this year is the KIACTA™ Phase 3 Confirmatory Study top-line results, which are expected before the end of June".

Following the transaction, the Company will have approximately 61.1 million common shares outstanding and will continue to have approximately 65.9 million common shares on a fully diluted basis, taking into account approximately 4.8 million common shares issuable under the Company's stock option plan.

Following the transaction, Pharmascience will hold 6,350,638 common shares of the Company, representing 10.4% of the Company's issued and outstanding common shares (9.6% on a fully diluted basis).

Pharmascience first acquired the Units in connection with the strategic partnership entered into with BELLUS Health on May 25, 2012. Pharmascience did not convert the Units with a view to materially affect control of BELLUS Health.



Bullboard Posts